SuperworthScilex EPS SCLX
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- −$16.65
- Fiscal year 2024
- −$17.98
Scilex's twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was −$16.65.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2024 | −$17.98 | n/a |
| FY2023 | −$44.10 | n/a |
| FY2022 | −$5.95 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$16.65 | n/a | n/a | |
| Q1 FY26 | −$6.28 | n/a | n/a | |
| Q3 FY25 | −$22.17 | n/a | −$33.25 | |
| Q2 FY25 | −$7.42 | n/a | −$11.66 | |
| Q1 FY25 | −$2.26 | n/a | −$11.91 | |
| Q4 FY24 | −$1.40 | n/a | −$17.98 | |
| Q3 FY24 | −$0.58 | n/a | −$24.28 | |
| Q2 FY24 | −$7.67 | n/a | −$45.75 | |
| Q1 FY24 | −$8.33 | n/a | −$44.73 | |
| Q4 FY23 | −$7.70 | n/a | −$44.10 | |
| Q3 FY23 | −$22.05 | −494% | −$40.95 | |
| Q2 FY23 | −$6.65 | n/a | −$13.30 |
Against its peers
Companies in Healthcare nearest Scilex's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| SCLXScilex | n/m | |
| NEPHNephros | $0.16 | +33% a year |
| ATNMActinium Pharmaceuticals | $0.36 | |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| ICCCImmucell | $0.08 | −58% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| PDEXPro DEX | $4.11 | +52% a year |
| Peer median | $0.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Scilex
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.